Subscribe to our blog
Posted 13 July 2023 by
Frederik Jaenen
VP of Sales @ Binocs

Business process automation: accelerating change in the pharma sector

In my previous blog post, I explored the journey toward digitalization in pharma laboratories from a purely process-based perspective. Continuing the theme of process integration, this week I want to delve deeper into attitudes around business process automation in pharma companies and why simply implementing advanced digital systems is insufficient on its own—those systems must also communicate seamlessly with one another. Using digital scheduling as an illustrative example, I will demonstrate a stepwise journey that showcases the five levels of maturity in business process integration—from functionally isolated ways of working to delivering a fully optimized and automated digital ecosystem.

In a rush? Here are the 3 key takeaways

  1. 👉 Establishing process integration between the different stakeholders in the product release pipeline is a critical step towards achieving streamlined service delivery
  2. 👉 Implementing seamless digital integration between different software solutions is a logical and necessary aspect of digital transformation, and companies should be ambitious in order to futureproof their business processes
  3. 👉 There are 5 levels of integration that can be achieved between the planning systems of different stakeholders; industry standard is Level 2 and industry best practice is to achieve Level 3, but Binocs already offers Level 4 integration

The end-to-end pharma release pipeline has evolved into a highly complex business process in recent years. Changes such as the increased centralization of laboratory operations place higher expectations upon the various E2E stakeholders, typically with limited or no additional resources. In light of escalating demand for more products, faster, pharmaceutical companies face the challenge of managing intricate procedural integrations between different teams, departments, and even between geographically separate sites. In this dynamic environment, it has become evident that traditional business processes are insufficient as they move toward progressively greater levels of automation.

As I outlined in the previous blog post, Towards a paperless future: the path to lab automation“, increasing AI enablement in pharma lab business processes will only grow in importance over the coming decade, as such automation becomes a top priority for end-to-end processes; however, as digital management systems progress along that pathway of artificial intelligence and automation, new challenges will quickly begin to emerge. With each system being tailored to overcome the complexity of specialized requirements (and thus to deliver focused optimizations), there will be a corresponding need for those systems to communicate critical data to one another.

At present, many pharma companies are struggling to keep pace with both their own evolving requirements and the technologies developed to address them, especially when it comes to digital planning and scheduling. That’s why it serves as a useful example to illustrate the five different levels of maturity that exist for process integration and to highlight how organizational leadership in the biosciences sector may want to aim slightly higher in their digital transformation ambitions.

Diagram illustrating the progression through the 5 levels of maturity in business process automation

Maturity level 1: functional isolation

The first level of maturity in process integration represents the status quo for pharma companies until about a decade ago: siloed procedures, specific to narrow requirements, all working in isolation. In the context of planning work, each functional group within the end-to-end product release supply chain operated behind a Chinese wall, each with its separate processes, and with limited (if any) support from dedicated digital tools.

In this model, every planning stakeholder within the product release ecosystem scheduled their operations independently, perhaps with some shared goal-setting but with effectively zero cross-functional alignment on process and no standard practices for mitigating deviations and other delays.

Maturity level 2: cross-functional issue mitigation

In the last ten years, pharmaceutical companies have progressed towards a more cross-functional approach. This is partially as a result of the increased adoption of digital systems in that same period, with tools such as Excel being used to collect, collate, analyze, and address issues identified via more traditional means (emails, phone calls, and recurring meetings, both within and between departments). This allows response and execution processes to be established to collaboratively tackle challenges that span multiple departments.

For planning and scheduling, this cooperative approach is characterized by S&OP (Sales and operations planning) activities, whereby Management from different functional stakeholders meets to align on strategy, with the goal of overcoming blockers to streamline the production, inventory, sales and financial plans. For a lot of pharma companies, this represents the current industry standard, with only some functions (for instance, Production) using dedicated digital planning tools and often developing end-to-end plans with minimal input from certain key stakeholders.

Maturity level 3: sequential integration

It is generally recognized that there are distinct advantages to adopting digital solutions that can handle the specialized, repetitive, and computationally complex tasks that are relevant to different departmental responsibilities. In parallel, IT teams endeavor to establish a connected digital ecosystem that can facilitate communication and collaboration between departments and, to some extent, between different solutions.

This is certainly the direction of travel for planning in pharma companies today; for most, it represents the aspirational best practice approach. Indeed, many of our customers subscribe to Binocs as part of a wider digital transformation strategy to implement dedicated systems for planning different functions (e.g. production and QC). Recently, they have also started using digital supply chain twins to derive smart parameters that can further help with process streamlining. Realizing this goal requires significant endorsement from senior leadership but can also generate considerable improvements in service level, utilization and planning outcomes.

Maturity level 4: handshake integration

At Binocs, we’re already working to deliver the next step—and what we anticipate will become the new industry gold standard for business process integration in end-to-end planning for pharma release. In our vision of handshake integration, we propose a joined-up approach to dynamically coordinate plans across the separate quality control (QC), manufacturing, and supply chain functions, with the goal of achieving a fully optimized goods release processing time (GRPT).

As outlined in our recent webinar and at LogiPharma 2023, Bluecrux is already piloting this approach in collaboration with OMP. By seamlessly integrating their Unison production planning software with Binocs for QC planning and Axon as the digital supply chain twin to generate high quality, differentiated parameters, we have delivered a coordinated rhythm between QC, manufacturing, and the wider supply chain.

Maturity level 5: concurrent optimization

While it may still be quite distant, the ultimate endpoint of this journey is for companies to implement a wholly mature and technologically advanced approach to process integration. In a planning context, we expect this to emerge as a fully integrated solution that concurrently optimizes scheduling across QC, manufacturing, Logistics, Plant Maintenance, and beyond.

This comprehensive, end-to-end approach would represent the pinnacle of digital transformation, enabling complete operational optimization, driving efficiency, reducing lead times, and enhancing resource utilization. This long term ambition would also promote real-time decision-making, agility, and responsiveness to market demands.


  • Most life science organizations working towards greater cross-functional integration within their product release pipeline are currently at maturity level 2 (interdepartmental conversations with some shared planning but a small amount of digital support limited to only certain teams).
  • Those companies that have already implemented Binocs QC scheduling are ahead of the pack, typically representing a level 3 maturity of process integration (dedicated planning tools for different functions but with limited communication between them or end-to-end planning processes).
    • This remains the best practice, towards which all companies should be aiming as a minimum.
  • More companies are exploring ways to future-proof their production pipeline by integrating Quality Control and Supply Chain planning processes and systems to achieve a reduced GRPT.

Interested to learn how Binocs could integrate with your production planning and supply chain solutions to improve overall service levels? Reach out today for more information!

Let’s have a chat

Book a demo